Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers

BACKGROUND: Mortalin is enriched in a large variety of cancers and has been shown to contribute to proliferation and migration of cancer cells in multiple ways. It has been shown to bind to p53 protein in cell cytoplasm and nucleus causing inactivation of its tumor suppressor activity in cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Putri, Jayarani F., Bhargava, Priyanshu, Dhanjal, Jaspreet Kaur, Yaguchi, Tomoko, Sundar, Durai, Kaul, Sunil C., Wadhwa, Renu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923857/
https://www.ncbi.nlm.nih.gov/pubmed/31856867
http://dx.doi.org/10.1186/s13046-019-1500-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923857/
https://www.ncbi.nlm.nih.gov/pubmed/31856867
http://dx.doi.org/10.1186/s13046-019-1500-9

Ejemplares similares